MICHAEL R MIGDEN to Molecular Targeted Therapy
This is a "connection" page, showing publications MICHAEL R MIGDEN has written about Molecular Targeted Therapy.
Connection Strength
0.500
-
Treatment of advanced cutaneous squamous cell carcinoma: a Mohs surgery and dermatologic oncology perspective. Future Oncol. 2021 Dec; 17(35):4971-4982.
Score: 0.094
-
CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma. Future Oncol. 2020 Feb; 16(4):11-19.
Score: 0.083
-
Disseminated anaplastic pleomorphic xanthoastrocytoma with posttreatment fat necrosis during combined BRAF and MEK inhibitors therapy. Pediatr Blood Cancer. 2019 12; 66(12):e27974.
Score: 0.081
-
Review of systemic agents in the treatment of advanced cutaneous squamous cell carcinoma. Future Oncol. 2019 Sep; 15(27):3171-3184.
Score: 0.081
-
Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Na?ve and Previously Treated Basal Cell Carcinoma. Clin Cancer Res. 2018 05 01; 24(9):2082-2091.
Score: 0.073
-
Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial. Future Oncol. 2018 Mar; 14(6):515-525.
Score: 0.071
-
Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nat Commun. 2016 08 30; 7:12601.
Score: 0.016